{
    "clinical_study": {
        "@rank": "16885", 
        "arm_group": [
            {
                "arm_group_label": "Nefazodone", 
                "arm_group_type": "Active Comparator", 
                "description": "Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks."
            }, 
            {
                "arm_group_label": "Matched Placebo Tablet", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is the use of Nefazodone in the treatment of cocaine dependence\n      and depression comorbidity."
        }, 
        "brief_title": "Nefazodone in the Treatment of Cocaine Dependence and Depression - 4", 
        "condition": [
            "Cocaine-Related Disorders", 
            "Substance-Related Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cocaine-Related Disorders", 
                "Substance-Related Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objective of this study is to determine the safety and efficacy of nefazodone (Serzone )\n      in depressed cocaine dependent subjects. This is a hypothesis-testing study which will\n      explore whether cocaine usage will be reduced in the nefazodone treatment group compared to\n      a placebo control group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        DSM-IV diagnosis of cocaine dependence, Depression score of 12 or above and history of\n        depression. Males and non-pregnant, non-nursing females 21-55 years of age.\n\n        Exclusion Criteria:\n\n        Axis I diagnosis other than substance use disorder, major depression, anxiety of dysthymic\n        disorder. Physiological dependence on alcohol. Significant medical or neurological\n        history. Abnormal UA, CBC or Chem 23 (LFT's may be up to 3 times normal). Enrollment in an\n        opiate-substitution treatment program within 45 days of enrollment in the present study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00015210", 
            "org_study_id": "NIDA-5-0013-4", 
            "secondary_id": "Y01-5-0013-4"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Nefazodone", 
                    "Matched Placebo Tablet"
                ], 
                "intervention_name": "Nefazodone", 
                "intervention_type": "Drug", 
                "other_name": "Serzone"
            }, 
            {
                "arm_group_label": [
                    "Nefazodone", 
                    "Matched Placebo Tablet"
                ], 
                "description": "All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.", 
                "intervention_name": "Psychosocial Treatment", 
                "intervention_type": "Behavioral", 
                "other_name": [
                    "Indivdual Manual-quided relapse prevention therapy", 
                    "or Individual Dug Counseling"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nefazodone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02118"
                }, 
                "name": "Boston University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Nefazodone in Cocaine Dependent Subjects", 
        "overall_official": {
            "affiliation": "Boston University", 
            "last_name": "Dom Ciraulo, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 1999", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Natural log BE in urine samples collected weekly were analyzed for the baseline week and the subsequent 8 treatment weeks.", 
            "measure": "Urine benzoylecgonine (BE) concentration", 
            "safety_issue": "No", 
            "time_frame": "Study Weeks Basekine to Week 8"
        }, 
        "reference": {
            "PMID": "15730347", 
            "citation": "Ciraulo DA, Knapp C, Rotrosen J, Sarid-Segal O, Ciraulo AM, LoCastro J, Greenblatt DJ, Leiderman D. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction. 2005 Mar;100 Suppl 1:23-31."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00015210"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Boston Medical Center", 
            "investigator_full_name": "Dominic Ciraulo", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "HAM-D collected on a weekly basis.", 
                "measure": "Hamilton Depression Scale (HAM-D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Week 8"
            }, 
            {
                "description": "CCS scores were collected on a weekly basis.", 
                "measure": "Cocaine-Craving Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 8"
            }, 
            {
                "description": "Data for adverse events were collected on a weekly basis", 
                "measure": "Adverse Events Self Report", 
                "safety_issue": "Yes", 
                "time_frame": "Study Weeks  1 through 8"
            }, 
            {
                "description": "Subjects were asked about the amount of cocaine consumed and the number of days in cocaine was used in the previous week, on a weekly basis.", 
                "measure": "Alcohol Drug Use Inventory", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Study Week 8"
            }
        ], 
        "source": "Boston Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Boston University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Boston Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }, 
    "geocoordinates": {
        "Boston University": "42.358 -71.06"
    }
}